

16 PM

103C

PTO/SB/17 (01-03)

Approved for use through 04/30/2003. OMB 0651-0032

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2003

Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$)
180.00

Complete if Known

Application Number 10/018,453
Filing Date October 30, 2001
First Named Inventor Zabeau et al.
Examiner Name Arun Chakrabarti
Group Art Unit 1634
Attorney Docket No. 29314/35410A

METHOD OF PAYMENT (check all that apply)

☒ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None

☐ Deposit Account

Deposit Account Number

13-2855

Deposit Account Name

MARSHALL, GERSTEIN & BORUN

The Commissioner is hereby authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☒ Credit any overpayments

☐ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1001	750	2001	375	Utility filing fee	
1002	330	2002	165	Design filing fee	
1003	520	2003	260	Plant filing fee	
1004	750	2004	375	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1) (\$)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims	- 20 =		
Multiple Dependent	- 3 =		

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	84	2201	42	Independent claims in excess of 3
1203	280	2203	140	Multiple dependent claim, if not paid
1204	84	2204	42	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	410	2252	205	Extension for reply within second month	
1253	930	2253	465	Extension for reply within third month	
1254	1,450	2254	725	Extension for reply within fourth month	
1255	1,970	2255	985	Extension for reply within fifth month	
1401	320	2401	160	Notice of Appeal	
1402	320	2402	160	Filing a brief in support of an appeal	
1403	280	2403	140	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,300	2453	650	Petition to revive - unintentional	
1501	1,300	2501	650	Utility issue fee (or reissue)	
1502	470	2502	235	Design issue fee	
1503	630	2503	315	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	750	2809	375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	750	2810	375	For each additional invention to be examined (37CFR 1.129(b))	
1801	750	2801	375	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)
180.00

SUBMITTED BY

Name (Print/Type) Nabeela R. McMillian

Registration No. (Attorney/Agent)

43,363

Complete (if applicable)

Telephone (312) 474-6300

Signature

Nabeela R. McMillian

Date

May 1, 2003

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: May 1, 2003

Signature:

Nabeela R. McMillian

(Nabeela R. McMillian)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: May 1, 2003

Signature:

Nabeela R. McMillian
Nabeela R. McMillian

Docket No.: 29314/35410A
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Zabeau *et al.*

Application No.: 10/018,453

Group Art Unit: 1634

Filed: October 30, 2001

Examiner: Arun Chakrabarti

For: **DIAGNOSTIC SEQUENCING BY A
COMBINATION OF SPECIFIC CLEAVAGE
AND MASS SPECTROMETRY**

INFORMATION DISCLOSURE STATEMENT (IDS)

Box Patent Application
Commissioner for Patents
Washington, DC 20231


Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO - 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

All patents and publications in the attached Form PTO - 1449 are supplied herewith. It is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for the instant application under any section of 35 U.S.C. §102 or 35 U.S.C. §103.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

05/06/2003 15:16:50 00000018 10018453 180.00 00
01 FC:1806




Application No.: 10/018,453

Docket No.: 29314/35410A

This Information Disclosure Statement is being filed after the receipt of a first office action. It is filed to make of record publications discussed in a response to an office action in the present case. A fee pursuant to 37 C.F.R. §1.17(p) for the filing of the Information Disclosure Statement is attached herewith. No additional fees are believed to be necessary, however, the Commissioner is hereby authorized to charge any deficiency in the fees filed or credit any overpayments to our Deposit Account No. 13-2855. A duplicate copy of this paper is enclosed.

Dated: May 1, 2003

Respectfully submitted,

By .

Nabeela R. McMillian

Registration No.: 43,363
MARSHALL, GERSTEIN & BORUN
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorneys for Applicants

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAttorney Docket No.
29314/35410ASerial No
10/018,453

INFORMATION DISCLOSURE STATEMENT

Applicant
Zabeau *et al.*Filing Date
October 30, 2001Group
1634

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date if Appropriate
	A1	5,210,412	05/11/1993	Levis <i>et al.</i>	250	288	
	A2	5,453,247	09/26/1995	Beavis <i>et al.</i>	422	68.1	
	A3	5,547,835	08/20/1996	Köster	435	6	
	A4	5,580,733	12/03/1996	Levis <i>et al.</i>	435	6	
	A5	5,849,542	12/15/1998	Reeve <i>et al.</i>	435	91.1	
	A6	5,851,765	12/22/1998	Köster	435	6	
	A7	5,869,240	02/09/1999	Patterson	435	6	
	A8	5,869,242	02/09/1999	Kamb	435	6	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation Yes	No
	B1	EP 0 103 677	03/28/1984	EPO				X
	B2	EP 0 534 858	03/31/1993	EPO			X	
	B3	WO 94/21663	09/29/1994	PCT			X	
	B4	WO 96/29431	09/26/1996	PCT			X	
	B5	WO 96/36986	11/21/1996	PCT			X	
	B6	WO 97/33000	09/12/1997	PCT			X	
	B7	WO 98/03684	01/29/1998	PCT			X	
	B8	WO 98/12355	03/26/1998	PCT			X	
	B9	WO 98/20166	05/14/1998	PCT			X	
	B10	WO 98/40520	09/17/1998	PCT			X	
	B11	WO 98/45700	10/15/1998	PCT			Abstract	
	B12	WO 98/54571	12/03/1998	PCT			X	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C1	Aurup <i>et al.</i> , <i>Biochemistry</i> , 31 : 9636-9641 (1992)
C2	Bachem <i>et al.</i> , <i>The Plant Journal</i> , 9 : 745-753 (1996)
C3	Bonnin <i>et al.</i> , <i>J. Mol. Biol.</i> , 290 : 241-251 (1999)
C4	Cannistraro <i>et al.</i> , <i>Eur. J. Biochem.</i> , 181 : 363-370 (1989)
C5	Clayton <i>et al.</i> , <i>Curr. Opin. Microbiol.</i> , 1 : 562-566 (1998)
C6	Conrad <i>et al.</i> , <i>Nucleic Acids Res.</i> , 23 : 1845-1853 (1995)
C7	Contreras <i>et al.</i> , <i>FEBS Lett.</i> , 16 : 281-283 (1971)
C8	Crain <i>et al.</i> , <i>Curr. Opin. in Biotechnol.</i> , 9 : 25-34 (1998)
C9	Eckstein, <i>Ann. Rev. Biochem.</i> , 54 : 367-402 (1985)
C10	Eng <i>et al.</i> , <i>Nature Biotechnol.</i> , 15 : 422-426 (1997)
C11	Fleischmann <i>et al.</i> , <i>Science</i> , 269 : 496-512 (1995)
C12	Gao <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 94 : 407-411 (1997)
C13	Gish <i>et al.</i> , <i>Nucleic Acids Symp. Ser.</i> , pp. 253-256 (1987)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAttorney Docket No.
29314/35410ASerial No.
10/018,453

INFORMATION DISCLOSURE STATEMENT

Applicant
Zabeau *et al.*Filing Date
October 30, 2001Group
1634

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C14	Gish <i>et al.</i> , <i>Science</i> , 240 : 1520-1522 (1988)
C15	Hahner <i>et al.</i> , <i>Nucleic Acids Res.</i> , 25 : 1957-1964 (1997)
C16	Hertogs <i>et al.</i> , <i>Antimicrob. Agents Chemother.</i> , 42 : 269-276 (1998)
C17	Isola <i>et al.</i> , <i>Anal. Chem.</i> , 71 : 2266-2269 (1999)
C18	Ivanova <i>et al.</i> , <i>Nucleic Acids Res.</i> , 23 : 2954-2958 (1995)
C19	Kikuya Kato, <i>Nucleic Acids Res.</i> , 23 : 3685-3690 (1995)
C20	Köster <i>et al.</i> , <i>Nature Biotechnol.</i> , 14 : 1123-1128 (1996)
C21	Landegren <i>et al.</i> , <i>Genome Res.</i> , 8 : 769-776 (1998)
C22	Lander <i>et al.</i> , <i>Science</i> , 265 : 2037-2048 (1994)
C23	Lee <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 92 : 8303-8307 (1995)
C24	Liang <i>et al.</i> , <i>Science</i> , 257 : 967-971 (1992)
C25	Limbach, <i>Mass Spectrom. Rev.</i> , 15 : 297-336 (1996)
C26	Lipshutz <i>et al.</i> , <i>Curr. Opin. in Struct. Biol.</i> , 4 : 376-380 (1994)
C27	Little <i>et al.</i> , <i>J. Am. Chem. Soc.</i> , 116 : 4893-4897 (1994)
C28	Loverix <i>et al.</i> , <i>Nature Struct. Biol.</i> , 5 : 365-368 (1998)
C29	Marotta <i>et al.</i> , <i>Biochemistry</i> , 12 : 2901-2904 (1973)
C30	Maxam <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 74 : 560-564 (1977)
C31	Meador <i>et al.</i> , <i>Eur. J. Biochem.</i> , 187 : 549-553 (1990)
C32	Milligan <i>et al.</i> , <i>Nucleic Acids Res.</i> , 15 : 8783-8798 (1987)
C33	Murray, <i>J. Mass Spectrom.</i> , 31 : 1203-1215 (1996)
C34	Nickerson <i>et al.</i> , <i>Nature Genet.</i> , 19 : 233-240 (1998)
C35	Nordhoff <i>et al.</i> , <i>J. Mass Spectrom.</i> , 30 : 99-112 (1995)
C36	Pieles <i>et al.</i> , <i>Nucleic Acids Res.</i> , 21 : 3191-3196 (1993)
C37	Prashar <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 93 : 659-663 (1996)
C38	Richterich <i>et al.</i> , <i>Nucleic Acids Res.</i> , 23 : 4922-4923 (1995)
C39	Risch <i>et al.</i> , <i>Science</i> , 273 : 1516-1517 (1996)
C40	Sanger <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 74 : 5463-5467 (1977)
C41	Schena <i>et al.</i> , <i>Science</i> , 270 : 467-470 (1995)
C42	Schinazi <i>et al.</i> , <i>Int. Antivir. News</i> , 4 : 95-107 (1996)
C43	Simoncsits <i>et al.</i> , <i>Nature</i> , 269 : 833-836 (1977)
C44	Smith, <i>Nature Biotechnol.</i> , 14 : 1084, 1087 (1996)
C45	Sousa <i>et al.</i> , <i>EMBO J.</i> 14 : 4609-4621 (1995)
C46	Stevens, <i>J. Bacteriol.</i> , 164 : 57-62 (1985)
C47	Steyaert, <i>Eur. J. Biochem.</i> , 274 : 1-11 (1997)
C48	Vos <i>et al.</i> , <i>Nucleic Acids Res.</i> , 23 : 4407-4414 (1995)
C49	Wodicka <i>et al.</i> , <i>Nature Biotechnol.</i> , 15 : 1359-1367 (1997)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.